MicroPort Scientific Corporation

2024 Annual Results

April 2025

MicroPort微创

Disclaimer

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

FORWARD-LOOKING STATEMENTS

Some information contained in this presentation contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words “believe”, “intend”, “expect”, "anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort’s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China and other countries that MicroPort operates in.

CONFIDENTIALITY

This presentation is confidential and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose.

Contents

Net Loss Substantially Reduced by Strategic Focus and Transformation Efforts

Steady Revenue Growth

Revenue

$1,031.1 mn ▲**10%** YOY

Net Loss Narrowed by

~59% YOY

Expanded Global Presence

Going-abroad Revenue

$95.8 mn ▲**85%** YOY

Enhanced Efficiency

Total Operating Exp. Ratio ▼**29** ppts

R&D Expense Ratio **40%**▶**21%** YOY

EBITDA Turning

POSITIVE

Improved Liquidity

Operating Cash Outflow

Narrowed **79%** YOY

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies.

Resilient Growth as Navigating the Complex and Dynamic Environment

Segment	Revenue	YoY Changes	China Revenue YoY Changes
Orthopedics	$252.7mn	▲6.2%	▲26.1%
CRM	$220.6mn	▲7.2%	▲51.3%

			Overseas Revenue YoY Changes
Cardiovascular	$165.7mn	▲9.9%	▲47.0%
Endovascular	$169.5mn	▲1.6%	▲99.4%
Neurovascular	$107.0mn	▲14.4%	▲137.6%
Structural Heart	$50.7mn	▲7.5%	▲108.3%
Surgical Robots	$36.0mn	▲146.0%	▲388.2%

Revenue by Segment



Revenue by Region



Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies.

Global Commercialization through Integrated Inter-group Platforms

~ 40
Key Countries

~ 20
Subsidiaries with complete function

1,800+
employees

670+
Sales & Mkt



YOY Revenue Growth
▲85%

5-year CAGR
▲56%

GloMatrix Platform

Going-abroad Business

HQ Going-abroad Platform

GloMatrix Platform

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies.

Disciplined R&D Investment Underpins Sustainable Development

Meaningful Innovations

39
NMPA Green Paths
No.1 in industry for 10 consecutive years

~250
Approved Innovative Products

1,300+
Overseas Approvals
400+ FDA 70+ CE

Well-Recognized Global Clinical Trial Evidence

TARGET series clinical trial for Firehawk cardiac stent

60th anniversary of our first pacemaker implantation

Medial-pivot knee system stands on over 20 years of clinically demonstrated history. A legacy of 98.8% survivorship and 95% patient satisfaction

2024 Registration Updates

58 Class III initial NMPA Approvals

9 NMPA Green Paths

249 Overseas Approvals including

4 FDA and **18** CE

2024 Innovation Metrics

Domestic

- **Firesorb®**
  Latest Generation of Bioresorbable Cardiac Stent
- **Decypher™ & Outsight®**
  IVUS Diagnostic System and Catheter pullback speed up to 40 mm/s



- **PLATINIUM™**
  First ever domestically produced ICD in China
- **Tubridge™ Plus Flow Diverter**

- **Evolution® CCK Revision Knee System**
- **Cratos® Branched Aortic Stent-Graft System**

Overseas



- **Cratos™ Thoracic Branch Stent Graft System**
  EU Custom-made Device
- **Evolution® Tibial Cones**
  FDA Approval

- **Toumai® Laparoscopic Surgical Robot**
  CE Mark
- **VitaFlow Liberty® TAVI System**
  CE Mark

- **ALIZEA™ BOREA™ and CELEA™ LBBAP label**
  CE Mark
- **Numen® Silk 3D Electronically Detachable Coil**
  FDA Approval & CE Mark

Note: refers to initial registration/approval during reporting period and as of 28 March 2025.

MicroPort®

Expanding Our Global Presence with Broad-based Capabilities

Innovation

Rooted Innovation DNA

200+
Disease

600+
Smart solutions

10,000+
Patents (incl. applications)

At Scale

Leadership in multiple medtech segments

Cardio Endo
Neuro TAVI
Ortho CRM
Surgical Robot

100+
Countries & Region covered in total

20,000+
Hospitals entered in total

Global

Comprehensive global sales platform

Integrates
Global resources

Leverages
Regional platforms to radiate sales coverage

Supports
Integrated sales for all segments and provides functional services

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies. 2. refers to initial registration/approvals of 28 March 2025.

Contents

Cardiovascular Business

China

- **Strengthened leading position**
  - **FY24 revenue** ▲**2.0%**YOY, among which the DES products consolidate **No.1 market share,** accessories revenue ▲**23.4%** YOY
  - **Expanded hospital coverage**: DES covered 3,500+ hospitals, balloon covered ~1,500 hospitals to date
- **Intensive product approvals:**
  - **13 NMPA approvals** including the new generation of bioresorbable scaffold Firesorb®
  - **1 NMPA Green Path** piezoelectric guide wire and piezoelectric therapy device
  - **1 CE** NOPURGE® OCT catheter
- **Strategic Integration: market promotion of the complete coronary solution embarks in 2025**



Non-China

- **Robust revenue growth**
  - **FY24 revenue** ▲**47.0%** YOY**,** among which **EMEA** ▲**60.6%** YOY Asia-Pacific (excluding China, ▲**54.0%** YOY) and Latin America (▲**23.6%** YOY)
- **Expanded overseas coverage**
  - **Extensive sales network**: DES sales covered 92 countries/regions, balloon covered 87 countries/regions
  - **Diversified & flexible product portfolio** to maintain a leading market position
- **Enhanced academic influence**
  - Key clinical studies on Firehawk® stent, including TARGET 3C, TARGET AC 5-year bifurcation subgroup, TARGET IV NA, and TARGET DAPT presented at global industry conferences

Redefine Our Line of Sight with Most Complete Portfolio Worldwide

Implant Device

Firebird2®
Rapamycin-Eluting Coronary Stent System
◆ **NMPA** approval

Firehawk®
Rapamycin Target Eluting Coronary Stent System
◆ **NMPA** approval

Intervention without Implantation



Firesorb®
Bioresorbable Rapamycin Eluting Coronary Scaffold System
◆ **NMPA** approval

Firelimus®
Coronary Rapamycin-Eluting Balloon Dilatation Catheter
◆ **NMPA** approval

FY2024&YTD approval

Access Device

Firefighter™
PTCA Balloon Catheter
◆ **NMPA** approval

FireFalcon®
Coronary Scoring Balloon Catheter
◆ **NMPA** approval

Bilumos®
Dual-lumen Catheter
◆ **NMPA** approval

Firefighter™ Pro mini
Coronary Balloon Dilatation Catheter
◆ **NMPA** approval

Active Device



TomaHawk®
Shockwave Intravascular Lithotripsy System
◆ **NMPA** approval

FireRaptor®
Rotational Atherectomy System
◆ **NMPA** approval

I-percker
intravascular piezoelectric guidewire system
◆ **NMPA GreenPath**
◆ **Upcoming NMPA Approval**

Imaging Diagnostic Devices

Argusclarity® Insight-100h
Optical Coherence Tomography System
◆ **NMPA** approval

Soul-Man™
Digital Subtracting Angiography System
◆ **NMPA** approval

Decypher®
Intravascular Ultrasound Imaging System
◆ **NMPA** approval

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies. 2. refers to initial registration/approvals of 28 March 2025.

MicroPort®

Orthopedics Business

Net loss substantially narrowed by 67.1%, positive EBITDA achieved

Revenue

USD: million



Business Highlights

China

- **FY24 revenue ▲ 26.1%YOY**, driven by rapid growth in both implantation volume and sales volume of hip and knee joint products
- Increased market share due to VBP execution and further expanded hospital coverage with regional coverage efficiency strategically enhanced
- Strict implementation of cost-control measures, **GPM improved 15.8 ppts**
- **FY24 operating expenses reduced by 19.6%YOY**
- New products approved: **NMPA approval** obtained for Evolution® CCK Revision Knee System and zirconium-niobium femoral condyle

Non-China

- **FY24 revenue ▲3.6%YOY, strong growth in the international markets (EMEA ▲16.8%YOY, Japan ▲7.2%YOY)** while US recovering from lingering impact from historical backorders (-8.1%YOY)
- **Sales revenue of knee portfolio ▲7.4% YOY**, driven by the growing recognition of the premium Medial Pivot Knee system & the successful execution of SkyWalker™ commercial strategy.
- **FY24 operating expenses reduced by 10.9%YOY**
- SkyWalker™ & Evolution® application with **~600 cases of TKA** surgeries performed
- Continuously improving global supply chain with suppliers being proactively diversified, backorders back to normal operating levels
- New product approval: Evolution® Tibial Cones obtained **FDA approval**

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies. 2. refers to initial registration/approvals of 28 March 2025.

MicroPort®

CRM Business

Net loss narrowed by 14.3% with improved EBITDA

Revenue

USD: million

Key products



Breakdown by region



Business Highlights

China

- **FY24 revenue** ▲**51.3%**YOY, with revenue of pacemakers ▲**56.1%**YOY; revenue of leads ▲**34.4 %**YOY
- **Accelerated market penetration** further consolidate **No. 1** market share among domestic pacemakers
- **GPM** improved by **11.3** ppts led by proactive dynamic adjustment of product mix and launch of new product ENO™ pacemakers
- **FY24 operating expenses reduced by 16.7%**YOY
- **Substantially enriched product pipeline: 5 NMPA approvals** including imported 1.5T/3T full-body MRI compatible **ENO™** series pacemaker**,** active fixation pacing leads **Vega™**, the first domestically made ICD **Platinum™**, MRI-compatible passive fixed pacing lead **BonaFire™**, 3.0T whole-body MRI-compatible **TEN™** series pacemaker

Non-China

- **FY24 revenue** ▲**3.4%**YOY upstream parts supply problem has been comprehensively solved
- **FY24 operating expenses reduced by 12.2%**YOY
- **Active new product promotion: 1st commercial implantation** of TALENTIA™ - ENERGYA™ ICDs & CRT-D in Europe, GALI™ CRT-D SonR® system in Japan and Alizea™ Bluetooth® pacemaker system in the US
- **1st step in the exploration of LBBAP solutions** : CE mark-MDR approval for ALIZEA™ family pacemakers featuring LBBAP, first patients enrollment in POLARIS Clinical Trial Using FLEXIGO™ Delivery Catheter System for LBBAP Implantations
- **Strategic Partnership** with Andhra Pradesh MedTech Zone (AMTZ) enables us to enter the rapidly growing and underpenetrated Indian CRM market (valued ~$115 mn & 15% annual growth rate)
- **CE Mark Approval and the Launch of** SmartView Connect™ App Mobile for its Bluetooth® enabled cardiac devices

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies. 2. refers to initial registration/approvals of 28 March 2025.

Endovascular Business

Key Financials



Business Highlights

China

- **FY24 revenue ▲1.6%YOY**, due to the introduction of industry policies in 2H24, while key products increased its hospital coverage and implant volume
- **Innovative products accelerate market penetration**: comprehensively covered 2,400 hospitals & saved 280,000+ patients to date
- **Intensive product approvals, especially in peripheral area:**

  9 NMPA approvals - Cratos®, L-REBOA®, Vewatch®, Vepack®, Vflower®, ReeAmber®, HawkNest™, SeaDragon™, Tipspear®

  1 NMPA Green Path - Hector®, the 1st triple-branch stent, further extending aortic endoluminal treatment to the entire aortic arch, addressing the urgent clinical needs

Non-China

- **FY24 revenue ▲99.4%YOY**, the proportion of overseas revenue increase from 6.9% in FY23 to 13.6% in FY 24
- **Rapid progressing global launch of core products**: Castor® entered into **22** countries, Minos® entered into **24** countries, Hercules® Low Profile entered into **24** countries
- **Swiftly advancing overseas sales channel**: its innovative products covered **40** markets accumulatively, across EU, Latin America and Southeast Asia
- **Achieved significant progress for NMPA products going abroad:**
  - **8** new certificates were obtained in overseas markets
  - Cratos® received the EU Customized Certificate
  - Hector® clinical trial implants in countries including Switzerland and Italy, with favorable surgical outcomes and recognition from international clinical experts

	Product	Pre-clinical	Clinical	Registration
Aortic Intervention	L-REBOA® Aortic Occlusion Balloon Catheter			✓ Obtained **NMPA approval**
	Cratos® Branched Aortic Stent-Graft System			✓ Obtained **NMPA approval**
				• Awarded the EU Customized Certificate
	Aegis® II Abdominal Aortic Stent-Graft System		• Conducting pre-market clinical trial	
	Hector® Multi-branched Aortic Stent-Graft System		• Conducting FIM clinical trial	
	Aortic Tear Flow-Restriction Stent		• Conducting FIM clinical trial	
Peripheral Venous Intervention	Vflower® Venous Stent System			✓ Obtained **NMPA approval**
	Vewatch® Vena Cava Filter			✓ Obtained **NMPA approval**
	Vepack® Filter Retriever			✓ Obtained **NMPA approval**
	Fishhawk® Mechanical Thrombectomy Catheter		• Completed pre-market clinical trial	
Peripheral Arterial Intervention	ReeAmber® Balloon Dilation Catheter			✓ Obtained **NMPA approval**
	HawkNest® Fibered Embolization Coil			✓ Obtained **NMPA approval**
	Below-The Knee Drug Coated Balloon Catheter		• Conducting pre-market clinical trial	
Oncological Intervention	HepaFlow® TIPS Stent Graft System		• Completed pre-market clinical trial	
	Tipspear® Transjugular Liver Access Set			✓ Obtained **NMPA approval**
	Polyvinyl Alcohol (PVA) Embolic Microspheres		• Conducting pre-market clinical trial	

Product admitted to NMPA Green Path

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies. 2. refers to initial registration/approvals of 28 March 2025.

MicroPort®

Neurovascular Business

Key Financials



Business Highlights

China

- **FY24 revenue ▲8.3%YOY**, key products recorded steady growth, accelerated hospital entry of new products
- **Coverage of high-quality hospitals accelerates market penetration**: ~**450** hospitals have been newly covered, with a total coverage of ~**3,400** hospitals, accumulated support for approximately **210,000** neuro-interventional surgeries
- **Product portfolio covers all neurovascular diseases: 9 NMPA approvals** spanning hemorrhagic stroke, CAS, AIS and access areas in FY24&YTD, **25** commercialized products to date, and with **11 candidates** under R&D

Non-China

- **FY24 revenue ▲137.6%YOY**, the proportion of overseas revenue increase from 4.8% in FY23 to 9.9% FY 24
- **Achieved significant progress for NMPA products going abroad:**
  - **8 products** commercialized in **30** overseas countries in total , covering 9 of the top 10 countries worldwide in terms of the number of neuro-interventional procedures
  - **NUMEN® Silk obtained FDA approval and CE Mark**
  - Tubridge® completed its **1st** commercial implantation
- **Continuously enhanced global academic influence**: research outcomes for Tubridge® was published in a leading neurosurgery journal and an SCI Q1 international core journal

	Product	Pre-clinical	Clinical	Registration
Hemorrhagic Stroke	Tubridge® Plus Flow-diverting Stent			✓ Obtained **NMPA approval**
	Numen® Silk 3D Electronically Detachable Coil			• NMPA approved ✓ Obtained **FDA approval & CE Mark**
	Numen® Uni Electronically Detachable Coil			✓ Obtained **NMPA approval**
	NuFairy™ Absorbable Coil Embolization System		• Conducting clinical trial	
	Rebridge® Intracranial Visualized Stent		• Conducting clinical trial	
CAS	Safecer™ Embolic Protection Device			✓ Obtained **NMPA approval**
	Pathfinder™ Carotid Artery Dilatation Catheter			✓ Obtained **NMPA approval**
	Intracranial Drug-Coated Balloon Catheter System		• Conducting clinical trial	
	Intracranial Autodistensible Drug Stent		• Design Validation	
	Intracranial Bulbar Expansion Drug Stent		• Design Validation	
AIS	Neurohawk® Pass17/21 Stent Thrombectomy Device			✓ Obtained **NMPA approval**
	NeuroGuard® Balloon Protection Guide Catheter			✓ Obtained **NMPA approval**
Access Product	17 Microcatheter		• Design Validation	

Product admitted to NMPA Green Path

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies. 2. refers to initial registration/approvals of 28 March 2025.

MicroPort®

Structural Heart Diseases Business

Key Financials



Business Highlights

China

- **FY24 revenue ▲4.0%[YOY]**, primarily attributable TAVI products & procedural accessories in the PRC
- **Increased hospital coverage**:
  - TAVI explored new access to **80** with **630+** hospitals coverage in total
  - AnchorMan® achieved **350+** clinical applications in **50+** centers across **15** provinces
- **2 NMPA Approvals:**
  - AnchorMan® LAAC System, China's first semi-closed left atrial appendage occluder
  - VitaFlow Liberty® Flex Transcatheter Aortic Valve Implantation System
- **Debut the global first "AFib One-Stop" radiofrequency ablation + left atrial appendage closure solution with Everpace**

Non-China

- **FY24 revenue ▲108.3% [YOY]**, core products accelerate the development and layout of overseas markets
- **2 CE Marks obtained**: **VitaFlow Liberty® & AnchorMan® LAAC System**
- **Expanded global presence:** TAVI products have been introduced into ~**100** core hospitals in **20+** countries and regions overseas, treating over **10,000** patients to date
- **Alwide® Plus** entered the key stages of CE mark registration
- **AltaValve™ was granted two breakthrough device designations by the FDA, and initiated a new pivotal study in Europe and the US**

	Product	Pre-clinical	Clinical	Registration
TAVI	VitaFlow®	• NMPA approved • Registered in Argentina and Thailand		
TAVI	VitaFlow Liberty®	• NMPA approved • Obtained CE Mark • Registered in 16 countries/regions		
TAVI	VitaFlow Liberty® Flex	✓ Obtained **NMPA approval**		
TAVI	VitaFlow® IV	• Design stage		
TAVI	AR product *(Self-developed)*	• Design stage		
Accessories	Alwide® Plus Balloon Catheter	• NMPA approved • Registered in 10 countries/regions • CE Marking in progress		
Accessories	AccuSniper™ Double Layer Balloon Catheter	• NMPA approved		
Accessories	Replacement product *(Self-developed)*	• FIM study		
TMV	AltaValve™ - Replacement product *(Partnership with 4C Medical)*	• Dual FDA Breakthrough Device • Pivotal study in the EU and US		
TMV	Replacement product *(Self-developed)*	• Design Stage		
TMV	Replacement product *(Partnership with 4C Medical)*	• Design Stage		
TTV	AnchorMan® Left Atrial Appendage Closure System	✓ Obtained **NMPA approval** ✓ Obtained **CE Mark**		
LAA products	AnchorMan® Left Atrial Appendage Access System	✓ Obtained **NMPA approval** ✓ Obtained **CE Mark**		
LAA products	New Gen. AnchorMan® Left Atrial Appendage Closure System	• Design Stage		
LAA products	New Gen. AnchorMan® Left Atrial Appendage Access System	• Design Stage		

Product admitted to NMPA Green Path

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies. 2. refers to initial registration/approval as of 28 March 2025.

MicroPort®

Surgical Robot Business

Key Financials



Business Highlights

China

- **FY24 revenue ▲84.4%YOY**, recorded robust sales growth and rapid pace of commercialization
- **Leading position among domestic brands**

Toumai®	R-ONE®
• **19** units of new commercial installation • **32** units of commercial installation base to date • **No.1** among domestic brands	• **2** units of commercialized installation • **7** orders obtained

- **Toumai® Single-port obtained NMPA approval**

Non-China

- **FY24 revenue ▲388.2%YOY**, the proportion of overseas revenue increase from 20.3% in FY23 to 40.2% FY 24
- **Toumai® obtained CE Mark**, along with registration approval in **~20** countries/regions
- **Ambitious Overseas Penetration**

Toumai®	SkyWalker™
• **11** units of new commercial installation • **Obtained 20+ orders** in FY24, covered Europe, Asia (ex-PRC), Africa and Latin America • Completed **300+** remote surgeries in overseas hospitals up to date • Created **25** records of 1st remote surgery globally	• **20+** new orders on the leverage of synergies with Orthopedics Business with **40+** orders in total up to date • Expanded to **20+** countries across **5** continents • ~2,000 TKA procedures globally to date

	Product	Pre-clinical	Clinical	Registration
Laparoscopic	Toumai® Laparoscopic Surgical Robot	• NMPA approved ✓ Obtained **CE mark**		
	Toumai® Remote Laparoscopic Surgical Robot	• Submitted for NMPA review		
	Toumai® Single-arm Laparoscopic Surgical Robot	✓ Obtained **NMPA approval**		
	DFVision® 3D Electronic Laparoscope	• NMPA approved • CE Mark		
Orthopedic	SkyWalker™ Orthopedic Surgical Robot	• NMPA approved ✓ Obtained **CE& FDA& ANVISA& TGA & CDSCO approval**		
Natural Orifice	Trans-bronchial Surgical Robot	• Submitted for NMPA review		
Panvascular	R-ONE® Panvascular Surgical Robot	✓ Obtained **NMPA approval**		
Percutaneous	iSR'obot® Mona Lisa Robotic Transperineal Prostate Biopsy System	✓ Obtained **NMPA approval**		

Product admitted to NMPA Green Path

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies. 2. refers to initial registration/approvals of 28 March 2025.

Contents

Financial Overview

Revenue



Operating Expenses (Amount)



Operating Expenses (%)



Finance Cost



Impairment Provisions



Gain from Asset Disposals



Note: revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies

MicroPort®

Significant Financial Improvement

Net Loss

USD: million



YoY Narrowing

59%

Non-HKFRS Adjusted Net Loss

USD: million



YoY Narrowing

49%

EBITDA

USD: million



Turning

Positive

MicroPort®

Eyes for greatness
Hands on details

MicroPort®

Innovative Product Pipeline Consistently Expanding Our Opportunities

Cardio-vascular	Piezoelectric Guidewire Equipment	Piezoelectric Guidewire accessorie 	Firehawk® FDA 	Coronary Stent Graft System	Coronary Sinus Balloon Counterpulsation System	Coronary Laser Ablation System	Guide Extension Catheter
Orthopedics	New Primary Knee System	Nexus Hip Stem	Procotyl P Acetabular Cup	Procotyl P Dual Mobility Cup	Wrist Joint Prosthesis System	3D-Printed Joints 	Shoulder Arthroplasty Product
CRM	Vega New Model 	Flexigo: LBBAP delivery kit 	Falcon6 	LINEA LBBAP 	Tilen & Eylen BLE MRI ICDs 	Smarview connect 	Alizea Bluetooth 
Endo-vascular	Aegis® II Abdominal Aortic Stent Graft System	TIPS Stent Graft System	Below-the-Knee (BTK) Drug-Coated Balloon Dilation Catheter	Detachable Fibered Embolization Coil	Mechanical Thrombectomy Catheter	Thrombus Protection Device	Peripheral Vascular Drug-Eluting Stent
Neuro-vascular	NuFairy™ Absorbable Coil Embolization System	Bridge® Vertebral Artery Bridge-MAX	Rebridge® Intracranial Visualized Stent	– Intracranial Drug-Coated Balloon Catheter System	Intracranial Autodistensible Drug Stent	Intracranial Bulbar Expansion Drug Stent	Self-Expanding Drug-Eluting Stent
Structural Heart	VitaFlow® IV 	Self- developed AR Product	Next Gen. AnchorMan® LAAC & LAAA System 	Self-developed TMV Product	Self-developed TTV Product	Alwide® Plus Balloon Catheter	AltaValve™ - Partnership with 4C Medical 
Surgical Robot	Toumai® Remote Laparoscopic Surgical Robot 		Toumai® Multiport Laparoscopic Surgical Robot Upcoming overseas approvals	SkyWalker™ Orthopedic Surgical Robot Upcoming overseas approvals 	Trans-bronchial Surgical Robot 		
Electro-physiology[1]	Pressure-Sensing Magnetically Guided Irrigated Pulsed-Field Ablation Catheter		Dual-Curve Pressure-Sensing Magnetic Radiofrequency Ablation Catheter	Mesh High-Density Mapping Catheter	Renal RF Ablation System	Flashpoint® Renal Artery Ablation Catheter	Ultrasound Imaging System

Note: 1. Electrophysiology business is a associated company

MicroPort®

Consolidated Income Statement

USD'000	2024	2023	Var.
Revenue	1,031,063	950,725	8.5%
Cost of sales	(456,971)	(418,627)	9.2%
Gross profit	**574,092**	**532,098**	**7.9%**
Research and development costs	(216,515)	(379,428)	-42.9%
Distribution costs	(304,154)	(334,939)	-9.2%
Administrative expenses	(178,891)	(201,688)	-11.3%
Other net income	29,359	49,514	-40.7%
Other operating costs	(13,260)	(12,747)	4.0%
Finance costs	(106,404)	(96,036)	10.8%
Changes in the fair value of convertible debts	(18,849)	(8,830)	113.5%
Changes in the fair value of other financial instruments	1,600	(4,171)	-138.4%
Impairment losses of non-current assets	(87,864)	(155,975)	-43.7%
Gain on disposal of subsidiaries	98,155	2,845	3350.1%
Gain on disposal of interests in equity-accounted investees	16,729	15,309	9.3%
Share of profits less losses of equity-accounted investees	(18,783)	(32,467)	-42.1%
Loss before taxation	**(224,785)**	**(626,515)**	**-64.1%**
Income tax	(43,674)	(22,642)	92.9%
Loss for the year	**(268,459)**	**(649,157)**	**-58.6%**
Attributable to: Equity shareholders of the Company	**(214,043)**	**(477,629)**	**-55.2%**

Consolidated Balance Sheet

USD'000	31 Dec 2024	31 Dec 2023	Var.
Non-current assets			
Investment properties	4,214	6,256	-33%
Property, plant and equipment	934,159	1,004,573	-7%
Intangible assets	234,317	234,435	0%
Goodwill	188,514	149,393	26%
Equity-accounted investees	382,861	372,637	3%
Financial assets measured at fair value through profit or loss ("FVPL")	9,883	10,003	-1%
Derivative financial assets	-	3,574	-100%
Deferred tax assets	18,488	31,382	-41%
Other non-current assets	123,713	109,705	13%
Total non-current assets	**1,896,149**	**1,921,958**	**-1%**
Current assets			
Financial assets measured at FVPL	51,817	40,028	29%
Inventories	379,288	414,868	-9%
Trade and other receivables	376,564	310,648	21%
Pledged deposits and time deposits	213,509	225,352	-5%
Cash and cash equivalents	712,995	1,019,551	-30%
Assets classified as held-for-sale	3,100	-	N/A
Total current assets	**1,737,273**	**2,010,447**	**-14%**
Current liabilities			
Trade and other payables	638,997	448,342	43%
Contract liabilities	19,863	18,770	6%
Interest-bearing borrowings	318,066	295,438	8%
Convertible bonds	147,133	549,470	-73%
Lease liabilities	40,143	46,915	-14%
Income tax payable	7,311	4,985	47%
Derivative financial liabilities	7,500	-	N/A
Total current liabilities	**1,179,013**	**1,363,920**	**-14%**
Net current assets	**558,260**	**646,527**	**-14%**

Consolidated Balance Sheet (cont'd)

USD'000	31 Dec 2024	31 Dec 2023	Var.
Non-current liablities			
Interest-bearing borrowings	757,711	508,330	49%
Lease liabilities	47,932	85,327	-44%
Deferred income	51,491	42,344	22%
Contract liabilities	26,948	27,669	-3%
Convertible bonds	374,224	213,267	75%
Other payables	24,124	262,865	-91%
Derivative financial liabilities	5,534	-	NA
Deferred tax liabilities	21,601	25,686	-16%
Total non-current liablities	**1,309,565**	**1,165,488**	**12%**
CAPITAL AND RESERVE			
Share capital	18	18	-
Reserves	603,455	757,801	-20%
Total equity attributable to equity shareholders of the Company	**603,473**	**757,819**	**-20%**
Non-controlling interests	541,371	645,178	-16%
Total equity	**1,144,844**	**1,402,997**	**-18%**